Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-05-14 Purchase | 2024-05-15 07:17 am | BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer | 30,000 | $5.86 | $175,800 | 272,139 (Direct) | View |
| 2023-04-03 Sale | 2023-04-05 4:33 pm | BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer | 7,000 | $8.29 | $58,030 | 207,275 (Direct) | View |
| 2022-12-15 Sale | 2022-12-19 4:58 pm | BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer | 3,125 | $10.89 | $34,031 | 133,275 (Direct) | View |
| 2022-04-01 Sale | 2022-04-04 4:32 pm | BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer | 7,600 | $16.2 | $123,120 | 136,400 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-03-31 Tax Withholding | 2024-04-02 4:21 pm | N/A N/A | BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer | 7,525 | $5.08 | 242,139 (Direct) | View |
| 2024-02-12 Disposition | 2024-02-12 4:47 pm | N/A N/A | ImmunoGen Inc. | IMGN | Thackray Helen M. Director | 152,759 | $0 | 0 (Direct) | View |
| 2023-12-29 Option Award | 2024-01-03 5:42 pm | N/A N/A | ImmunoGen Inc. | IMGN | Thackray Helen M. Director | 252 | $29.65 | 3,074 (Direct) | View |
| 2023-12-19 Tax Withholding | 2023-12-20 4:42 pm | N/A N/A | BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer | 5,580 | $6.05 | 249,664 (Direct) | View |
| 2023-12-14 Option Award | 2023-12-18 4:47 pm | 2024-12-14 2033-12-14 | BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer | 289,000 | $0 | 493,244 (Direct) | View |
| 2023-12-14 Tax Withholding | 2023-12-18 4:47 pm | N/A N/A | BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer | 3,031 | $6.43 | 493,244 (Direct) | View |
| 2023-09-29 Option Award | 2023-10-02 5:07 pm | N/A N/A | ImmunoGen Inc. | IMGN | Thackray Helen M. Director | 472 | $15.87 | 2,822 (Direct) | View |
| 2023-06-30 Option Award | 2023-07-05 5:52 pm | N/A N/A | ImmunoGen Inc. | IMGN | Thackray Helen M. Director | 397 | $18.87 | 2,350 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-16 4:50 pm | N/A N/A | ImmunoGen Inc. | IMGN | Thackray Helen M. Director | 32,687 | $0 | 32,687 (Direct) | View |
| 2023-03-31 Option Award | 2023-04-04 4:54 pm | N/A N/A | ImmunoGen Inc. | IMGN | Thackray Helen M. Director | 1,953 | $3.84 | 1,953 (Direct) | View |
| 2022-12-19 Option Award | 2022-12-21 4:41 pm | 2023-12-19 2032-12-19 | BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer | 319,000 | $0 | 452,275 (Direct) | View |
| 2022-06-15 Option Award | 2022-06-17 4:09 pm | N/A 2032-06-15 | ImmunoGen Inc. | IMGN | Thackray Helen M. Director | 32,066 | $3.37 | 72,998 (Direct) | View |
| 2022-06-15 Option Award | 2022-06-17 4:09 pm | N/A N/A | ImmunoGen Inc. | IMGN | Thackray Helen M. Director | 10,932 | $0 | 72,998 (Direct) | View |
| 2021-12-14 Option Award | 2021-12-16 5:06 pm | 2022-12-14 2031-12-14 | BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer | 249,000 | $0 | 349,000 (Direct) | View |
| 2021-09-22 Option Award | 2021-09-23 4:35 pm | N/A 2031-09-22 | ImmunoGen Inc. | IMGN | Thackray Helen M. Director | 44,000 | $5.97 | 74,000 (Direct) | View |
| 2021-09-22 Option Award | 2021-09-23 4:35 pm | N/A N/A | ImmunoGen Inc. | IMGN | Thackray Helen M. Director | 30,000 | $0 | 74,000 (Direct) | View |
| 2021-03-31 Option Award | 2021-04-02 5:26 pm | 2022-03-31 2031-03-31 | BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer | 500,000 | $0 | 500,000 (Direct) | View |
| 2021-01-20 Option Award | 2021-01-22 4:05 pm | N/A 2031-01-19 | GLYCOMIMETICS INC | GLYC | Thackray Helen M. SVP Clinical Development, CMO | 103,500 | $0 | 252,115 (Direct) | View |
| 2020-05-12 Option Award | 2020-05-14 4:36 pm | 2021-05-12 2030-05-12 | BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2020-01-22 Option Award | 2020-01-24 4:17 pm | N/A 2030-01-21 | GLYCOMIMETICS INC | GLYC | Thackray Helen M. SVP Clinical Development, CMO | 120,000 | $0 | 120,000 (Direct) | View |